Oxygen Biotherapeutics, Inc. to Present at Wall Street Analyst Forum Analyst Conference in New York City on Nov. 18

COSTA MESA, Calif.--(BUSINESS WIRE)--Oxygen Biotherapeutics, Inc. (OTCBB:OXBO) today announced that company chairman and CEO Chris J. Stern and CFO Charles Seeman will present at the Wall Street Analyst Forum Analyst Conference in New York on November 18, 2008 at 11:10 a.m. eastern time. The presentation will be webcast live and a replay will be available following the event on the company’s website. Webcast login information will be provided on the website prior to the presentation.

The company also announced that it has submitted an extensive document package about Oxycyte® to the FDA in advance of a meeting with the agency on Oct. 22. “I’m looking forward to this meeting as an opportunity to resolve any remaining issues and concerns the FDA may have for our Phase IIb trial for Oxycyte in traumatic brain injury,” said company chairman and CEO Chris J. Stern, DBA. “Our team will be there having done a lot of work to prepare for it.” Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier.

“We won’t be publicly announcing the details of what is discussed in the meeting on the 22nd. However, as soon as the agency informs us of a decision on the Phase IIb trial, we will make a public announcement,” Stern said.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and continuous substrate monitoring. The Company has under development a perfluorocarbon therapeutic oxygen carrier and liquid ventilation product and an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs and medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle-cell pain crisis, decompression sickness, stroke, heart attack, and wound treatment. For further information, visit www.oxybiomed.com.